• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Overweight and obesity are associated with improved survival, functional outcome, and stroke recurrence after acute stroke or transient ischaemic attack: observations from the TEMPiS trial
Conclusion Overweight and obese patients with stroke or TIA have better survival and better combined outcomes of survival and non-fatal functional status than patients with the BMI <25 kg/m2.
Source: European Heart Journal - January 21, 2013 Category: Cardiology Authors: Doehner, W., Schenkel, J., Anker, S. D., Springer, J., Audebert, H. J. Tags: Prevention Source Type: research

The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy
Conclusion The CHA2DS2-VASc score reclassifies 26% of patients with a CHADS2 score of 1 to a low annual risk of SSE of 1%. This risk seems low enough to consider withholding anticoagulant treatment.
Source: European Heart Journal - January 14, 2013 Category: Cardiology Authors: Coppens, M., Eikelboom, J. W., Hart, R. G., Yusuf, S., Lip, G. Y. H., Dorian, P., Shestakovska, O., Connolly, S. J. Tags: Arrhythmia/electrophysiology Source Type: research

Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden
Conclusion Dabigatran is a cost-effective treatment in Sweden, as its incremental cost-effectiveness ratio is below the normally accepted willingness to pay limit.
Source: European Heart Journal - January 14, 2013 Category: Cardiology Authors: Davidson, T., Husberg, M., Janzon, M., Oldgren, J., Levin, L.-A. Tags: Arrhythmia/electrophysiology Source Type: research

Deletion of the ageing gene p66Shc reduces early stroke size following ischaemia/reperfusion brain injury
Conclusion In the present study, we show that the deletion of the ageing gene p66Shc protects mice from ischaemia/reperfusion brain injury through a blunted production of free radicals. The ROS mediator p66Shc may represent a novel therapeutical target for the treatment of ischaemic stroke.
Source: European Heart Journal - January 6, 2013 Category: Cardiology Authors: Spescha, R. D., Shi, Y., Wegener, S., Keller, S., Weber, B., Wyss, M. M., Lauinger, N., Tabatabai, G., Paneni, F., Cosentino, F., Hock, C., Weller, M., Nitsch, R. M., Luscher, T. F., Camici, G. G. Tags: FASTTRACK BASIC SCIENCE Source Type: research

Pages: 1  2  3  4  5  6  7  8